Arunjayoti Bio Ventures Limited has announced a board meeting scheduled for February 3, 2026, to review its quarterly financial performance. The company informed BSE Limited through an official communication dated January 30, 2026, regarding the upcoming board deliberations.

Meeting Details and Agenda

The board meeting will be held at the company's registered office located at Door No.1-98/1/JSIC/6F/604-B 6th Floor, Jain Sadhguru Capital Park, Beside Image Gardens, Madhapur, Shaikpet, Hyderabad, 500081, Telangana. The meeting is scheduled for Tuesday, February 3, 2026.

Key Agenda Items

The board will consider two main items during the meeting. The primary focus will be on reviewing the unaudited financial results along with the Limited Review Report for the quarter ended December 31, 2025. Additionally, the board will address any other business matters with the permission of the Chair.

Corporate Communication

The official intimation was signed by Pabbathi Badari Narayana Murthy, Whole-Time Director of the company, bearing DIN: 01445523. The communication was digitally signed on January 30, 2026, at 12:34:15 +05'30', ensuring compliance with regulatory requirements under Regulation 30.

Company Information

Arunjayoti Bio Ventures Limited operates under scrip code 530881 on BSE Limited. The company maintains its registered office in Hyderabad's Madhapur area, specifically at the Jain Sadhguru Capital Park complex. The upcoming board meeting represents the company's commitment to timely disclosure of financial information to stakeholders and regulatory compliance.

Arunjyothi Bio Ventures Limited has reported a significant turnaround in its financial performance for the half-year ended September 30, 2025. The company's board of directors approved the unaudited financial results in a meeting held on November 3, 2025.

Key Financial Highlights

Financial Performance Analysis

Arunjyothi Bio Ventures has shown a remarkable improvement in its bottom line, reporting a profit before tax of ₹109.22 lakhs for the half-year period ended September 30, 2025. This is a significant turnaround from the loss of ₹24.10 lakhs reported in the previous corresponding period.

However, it's important to note that while profitability improved, the company's revenue from operations decreased by 14.6% year-over-year to ₹1,404.89 lakhs in H1 FY2026 from ₹1,644.92 lakhs in H1 FY2025.

Balance Sheet Highlights

The company's balance sheet as of September 30, 2025, shows:

• Total assets stood at ₹5,909.00 lakhs
• Equity share capital remained unchanged at ₹1,863.81 lakhs
• Cash and cash equivalents decreased to ₹7.38 lakhs from ₹59.21 lakhs as of March 31, 2025
• Non-current borrowings reduced to ₹1,494.71 lakhs from ₹1,677.23 lakhs as of March 31, 2025

Other Key Developments

Deferred Tax Adjustment

The company identified and corrected a prior period error relating to deferred tax computation on depreciation differences and recognition of previously unavailed tax benefits on unabsorbed depreciation. This adjustment is non-cash in nature and has no impact on the company's operating performance or cash flows.

Stock Split

During the quarter ended March 31, 2025, the company implemented a stock split, changing the face value of shares from ₹10 to ₹1 per share. This has affected the calculation of earnings per share for all reporting periods.

Conclusion

While Arunjyothi Bio Ventures has shown improved profitability in H1 FY2026, the decrease in revenue and cash reserves may warrant attention. The reduction in non-current borrowings could indicate a strengthening financial position, but investors should monitor the company's ability to maintain profitability and manage its working capital effectively in the coming quarters.